North America Implantable Neurostimulation Devices Market Size and Overview North America Implantable Neurostimulation Devices Market size was valued at USD 6.4 Billion in 2025 and is poised to grow f...

Cognitive decline begins in early stages of Parkinson's disease (PD) for many individuals and remains largely untreated. The nucleus basalis of Meynert (NBM), the brain's cortical cholinergic hub, and...

Publication date: Available online 2 November 2026 Source: Physiology & Behavior Author(s): Renata Moreira Acunha, Priscila Medeiros, Hélio Rubens Machado, Lourenço Sbragia, Norberto Cysne Coimbra, Sabatino Maione, Renato Leonardo de Freitas

An FDA-cleared wearable neurostimulation device is indicated for the temporary relief of hand tremor in essential tremor and Parkinson disease.

The 2027 World Conference on Interventional Pain Medicine & Neuromodulation (2027WIPN) is an international hybrid conference organized by Episirus

Background: Dysphagia is a common complication following stroke. While current management strategies for poststroke dysphagia (PSD) range from nutritional support to neurostimulation techniques, an optimal treatment regimen remains elusive. As a promising noninvasive neuromodulation approach, transcutaneous auricular vagus nerve stimulation (taVNS) requires further validation in rigorously designed trials to establish robust evidence of its efficacy and mechanisms of action. Objective: This #Study aims to validate the efficacy of taVNS in treating PSD and to elucidate its underlying mechanisms, thereby supporting the development of a novel, noninvasive therapeutic strategy for improving swallowing function in stroke survivors. Methods: This #Study will use a prospective, randomized, double-blind, controlled trial design. A total of 40 patients with PSD will be enrolled and randomly allocated to either a taVNS group or a sham taVNS group. Both groups will receive conventional swallowing rehabilitation therapy as the baseline intervention. The taVNS group will receive bilateral electrical stimulation at the cymba conchae and cavum conchae of the auricle. These sites correspond to the “Heart” and “Kidney” auricular acupoints, selected in accordance with traditional Chinese medicine theory. In contrast, the sham taVNS group will receive stimulation at regions of the auricle not innervated by the vagus nerve. The primary outcome measure will be the Penetration-Aspiration Scale score. Secondary outcomes will include the Yale Pharyngeal Residue Severity Rating Scale, hyoid bone displacement and hyoid-thyroid approximation distance assessed via B-mode ultrasonography, and motor-evoked potentials of the suprahyoid muscles elicited by transcranial magnetic stimulation. All outcome measures will be evaluated at baseline and after the 2-week intervention period. Results: This paper describes the #Protocol for a #Study evaluating the efficacy and mechanisms of taVNS in patients with PSD. The #Study was funded in January 2025. Participant recruitment began in March 2025 and is projected to conclude by October 2026. Data collection began in March 2025 and is projected to be completed by October 2026. Primary #Study results are expected to be submitted for publication in winter 2026. Conclusions: This #Study aims to validate the efficacy of taVNS in treating PSD and to elucidate its underlying mechanisms, thereby supporting the development of a novel, noninvasive therapeutic strategy for improving swallowing function in stroke survivors. Trial Registration: Chinese Clinical Trial Registry ChiCTR2500096311; https://tinyurl.com/yc2dz89r International Registered Report Identifier (IRRID): DERR1-10.2196/95182

Is inspiration enough to restore broken neurons and heal a brain injury? When strategies and opening the boxes of the new you fail, turn to neurostimulation!

The pursuit of lifelong cognitive wellness is entering an exciting new chapter as scientists investigate how medicinal mushrooms, traditional herbs, and

The Current Neurostimulation Market was valued at USD 8.5 billion in 2025 and is poised to grow from USD 9.

The Current Neurostimulation Market was valued at USD 8.5 billion in 2025 and is poised to grow from USD 9.

OBJECTIVE Despite advances in surgical and neuromodulatory treatments, a substantial proportion of patients with drug-resistant epilepsy remain ineligible for standalone resection or ablation. Combini...

Saluda Medical said on Wednesday it is undertaking a voluntary recall of certain Evoke ​neurostimulation devices after identifying a manufacturing-related issue, ‌sending shares of the US-based firm to a record low.

Saluda Medical said on Wednesday it is undertaking a voluntary recall of certain Evoke ​neurostimulation devices after identifying a manufacturing-related issue, ‌sending shares of the US-based firm to a record low.

Saluda Medical shares tumbled to a record low following the announcement of a voluntary recall affecting certain Evoke neurostimulation devices. The

Oklahoma lawmakers plan to revive Dylan’s Law II in 2027 to require insurance coverage for epilepsy treatments and neurostimulation devices.

The Nerve Stimulator Market is witnessing significant growth as healthcare providers increasingly adopt advanced neurostimulation technologies to manage chronic pain, neurological disorders, and movement-related conditions. The market size was valued at US$ 5.78 billion in 2025 and is projected to reach US$ 13.04 billion by 2033, registering a CAGR of 10.71% from 2026 to 2033. Increasing…